AMCIL Limited (AMH) Earnings Call Transcript & Summary
August 1, 2023
Earnings Call Speaker Segments
Robert Freeman
executiveAlright, good afternoon to all of you. As mentioned, my name is Mark Freeman, and I serve as CEO, Managing Director, and Portfolio Manager at AMCIL Limited. Welcome, then, to this briefing on the full year results. This marks the first one we've held for AMCIL following the result. To start, I want to acknowledge the traditional owners and custodians of all the lands on which we meet today, and to pay my respects to their elders, past, present, and emerging. With me on today's webinar are Olga Kosciuczyk from the investment team and Jaye Guy, also from the investment team; Andrew Porter, our CFO; Matthew Rowe, our Company Secretary; and Geoff Driver, our General Manager of Business Development. Before we begin the presentation, a few housekeeping notes about this webinar. This briefing draws on material available on the company's website. Should you be using your computer to access this presentation via the webcast, the slides will change automatically. If instead you are joining by phone only, a PDF of the slides with page numbers can be found on the website. Lastly, please be aware that after the presentation, there will be time for questions and answers. Questions can be submitted either through the webcast or via the operator. So, moving into the presentation. Slide 2 is the disclaimer, simply to note that we're here to discuss the company; no advice is being given. Then, on to Slide 4, the financial year in summary. I'll hand over to Andrew Porter to take you through that.
Andrew J. Porter
executiveThanks, Mark, and good afternoon, everyone. I'll go through these in sequence, starting at the top left and finishing at the bottom right. Profit came in at $7.6 million. On the face of it, that's lower than $8.1 million, but the $8.1 million figure from last year contained a $2 million scrip dividend tied to the BHP Woodside merger. Excluding that item, profit actually rose 24%. The remaining dividends were broadly higher than a year earlier, and so was the contribution from trading and options. That supported a declared final dividend of $0.025, the same as we've paid over the last couple of years, along with a $0.015 special, making $0.05 in total, compared with $0.035 the year before. The proceeds from realizing gains, especially those booked last year, helped fund that $0.015 special. Each year realized gains are drawn on to support the regular dividend, but given how strong the prior gains and reserves were, the Board judged a $0.015 special dividend to be appropriate. Once the final and special dividends have been paid, I should point out to shareholders that AMCIL retains the capacity, using franking credits, to pay a further $0.055 dividend. So our franking credit reserve remains fairly comfortable. The total portfolio return for the full year, franking included, was 13.5%, and Mark will cover that later in the year. We shifted from a premium to a discount. I'll address that shortly. Consequently, the shareholder return, meaning share price plus dividends and again including franking, fell 2.1%. The management expense ratio, the key gauge of what it costs to run the company, came in at 0.66%, compared with 0.52% last year. That works out to $0.66 per $100 invested. Two factors drove the increase. Expenses were reallocated to reflect the work AICS performs for AMCIL, and given how small the expense base is, that can have a disproportionate effect; the other roughly half of the rise came from the decline in average portfolio value. The way the MER is calculated is the year's cost divided by the year's average portfolio value. Average portfolio value was $384 million in 2022 and dropped to $339 million in 2023. So that clearly has an impact. As you can see, we finished the year at $346.1 million, and while that was higher than 2022, the average portfolio value is of course the average of each month across the years concerned. Moving to Slide 5, you'll see the NTA at the end of June stood at $1.12. The share price was $1.01. So we went from a premium of 4.5% in June 2022 to a discount of just under 10% this year. And that explains why the minus 2.1% shareholder return stands in such sharp contrast to the 13.5% portfolio return. That's all from me, though. I'll hand things back to Mark so he can walk through some of the portfolio figures and the returns.
Robert Freeman
executiveAlright, let’s turn to Slide 7, the performance figures. What you’re seeing here is how those numbers look once franking credits are included, or when performance is grossed up. That treatment is applied to both the Benchmark and AMCIL. On those measures, we’re trailing, and I’ll get into some of the reasons behind that in a moment. But again, I’d point out that AMCIL’s performance figures reflect performance only to the extent that franking credits have actually been paid out. As Andrew mentioned, we still hold a fairly substantial amount of franking credits inside the company, and those will only show up in these performance numbers once they’ve been distributed, so they definitely weigh on those figures. Turning to Page 8, the next slide, for more specifics about some recent weak results. Over the last twelve months, a handful of our bigger positions have lagged fairly noticeably. Our horizon is long term. We prefer to remain with businesses we broadly see as excellent ones to own for years. That stance, though, guarantees periods in which shares may stagnate or even decline. We have provided an illustration of several such cases, in a year when the index gained roughly 17%. Along the bottom row, you can see companies such as CSL, up just 4%; Mainfreight, 6%; Transurban, 3%. Regarding those three stocks, they've been meaningful positions and have been part of the portfolio for quite a while, though lately they've clearly lagged the market. Despite that, we remain confident they're solid businesses worth holding over the long haul. Moving to the following slide, here's another factor behind our recent weak results. On the left side, we have certain cyclical names, especially in resources: we're underweight materials and resources within the market. We hold BHP, along with some Santos and Woodside; however, as long-term investors, we view these once more as cyclical businesses, with their fluctuations, and we lean toward companies we'd call structural compounders. So that does mean if those sectors take off, we could lag, which has happened. Still, we lean toward the bigger resource names and keeping our position as it is. There were also a few stocks whose thesis didn’t work out. We’ve cited Tilos, Iris and PEXA, all of which we’ve now sold. Iris sat in the portfolio a long time and carried many of the traits we seek in companies, especially the annuity-style revenue streams they produce; it has delivered solid return on capital. But this business has a history that began in financial services and then expanded into Wealth Management, where it performed very well, and that is where the prior — the majority of the previous CDO came from; they put a lot into that area, and afterward they shifted to the U.K., which turned out to be quite difficult for them. And if you look back at their record, they simply were not producing any earnings growth or earnings per share growth, and once the CEO had departed the company, we chose to move on as well; so it has been somewhat disappointing for us. And PEXA, we put money into that company; we appreciate the nobly character of their business here in Australia. But there was likely some of it in the valuation when we invested for success coming out of the U.K. That has probably turned out to be somewhat more difficult for them, the stocks derated; we have chosen to exit that company for the time being. It remains very much on our watch list, since we like companies holding monopoly-type positions. But given the uncertainty surrounding the U.K., we simply chose to stay on the sidelines and continue watching that position for now. So perhaps it is time to restate our approach. Turning to AMCIL, please refer to Slide 10. That patent ought to become clear on the slides coming up next, which showcase several deals we've closed during the last six or seven months; our aim is to hold stakes in high-quality businesses. What you see here is essentially a checklist of the core traits we look for in any company we put money into. We lean toward businesses that either lead their industry or are on the way to doing so, and that own assets which are distinctive or extremely difficult to copy. We also lean toward businesses whose balance sheets are conservative. Companies carrying excessive debt make us wary. When we assess a business, we consider external factors that affect it, and we're wary of firms exposed to too many of them. Our preference is for businesses whose earnings are steadier, or whose revenue comes in an annuity-like form. There's also one element AMCIL treats as nonnegotiable: backing the people. So we need management to be effective. We like leadership teams that are passionate about their work. Ownership alignment is important too, and a lot of our companies are what we term owner-driver businesses — meaning the founders are still running the company. Why does this matter? When you put all of that together, what we've seen is that those results tend to produce an edge over rivals—and a durable one—at businesses in general, and that generates a strong return on capital. That, in turn, frees up more money to put toward growth, win additional market share, strengthen where we already lead, and produce earnings growth over the long haul. After all, at the end of the day, the stock market pays off for businesses that keep raising their earnings in a way they can sustain. I mentioned the Rolls-Royce businesses that come with a cyclical nature. What we're centered on is building value across the long term by means of the investments we make, and that leaves us holding a ranked roster of shares that could have been bought—but timing counts every bit as much as spotting value, so the thing we're hunting for is opportunity in price. The two areas we consider are either a trend that keeps going, meaning a stock may already have risen but we still believe there is a long runway of growth ahead, and in that case we are glad to buy, so that is a continuation of a trend, or a dislocation in price taking place. That could be some kind of event that pushes the share price down, which hands you a chance to buy a company well, or a discounted capital raising is another event that lets us buy well in good companies, and those are the frameworks we apply around our potential transactions. We'll go through a number of the things we've been doing over the last 6 months, and I'm very pleased with how the deals we've been making during this period have been generating value, and because of that, we're very pleased with the performance over the last 6 or 7 months. The discipline we'll maintain is simply to keep carrying forward that trend that we're about to lay out right now, so at this point I'll turn things over to Olga to discuss 3 of the companies we acquired. In certain cases we purchased a small amount. In certain cases we purchased a great deal. All these outcomes, though, always is to get total. When you review past deals and keep thinking you should have purchased a bigger stake, that shows we're headed in the right direction—and I'd say that holds true for every one of these deals. So, Olga, the floor is yours.
Olga Kosciuczyk
executiveThanks, Mark, and good afternoon to all of you. Across the following 3 slides, we show you some examples illustrating how the investment philosophy Mark just outlined gets applied to transactions within our portfolio. Worries in the market about what RBA interest rate prices imply for household disposable income and for the housing market led to a broad-based sell-off among consumer discretionary companies. We used these price dislocations to build up our high-quality holdings that satisfy our investment criteria: ARB, James Hardie and Reece. ARB is the founder-led top producer of forward drive accessories in Australia. Its leadership rests on outstanding engineering and high-quality products, which leading car manufacturers around the world recognize. More recently, ARB began making branded products for Ford and Toyota; we view this opportunity as a multiyear expansion of their growth runway. With that in mind, the recent pullback in price offered a chance to add to our holdings at a very attractive price. James Hardie leads in fiber cement home siding with a 90% market share. Fiber cement is a lightweight product with a wood look and feel. Fiber cement's superior performance relative to alternative products has translated into consistent market share gains in the U.S. residential housing market. The growth runway is long. Capital allocation has been strong, with the company generating a return on invested capital well above its cost while maintaining a strong balance sheet, which makes it an attractive long-term investment for our portfolio; and finally, we also added to our holding in Reece. Reece is an owner-driver business and Australia's largest plumbing and bathroom supplies company. We have high confidence in their management and believe they can replicate their Australian success in the U.S., where they entered the market only 5 years ago via an acquisition. This gives Reece a large growth opportunity for years ahead and a stable holding for our portfolio. And I will now pass to Jaye.
Robert Freeman
executiveLet me just start. I really hope the slide makes this obvious. A small green dot indicates where we were purchasing. I didn’t call that out on the slide, so it may be difficult to see. But if your slides are in color, you’ll notice the green dots; that’s when we’re buying those companies. Sorry, Jaye.
Jaye Guy
executiveThanks, Mark and Olga. Hello, everyone, and good afternoon. If you look at Slide 12, we show some cases where AMCIL took advantage of short-lived mispricing to add to positions in store companies at attractive values. A lot of people on this call will be familiar with Medibank, a top health insurer in Australia. We have followed it closely since its IPO, drawn by its leading place in an essential sector, plus a solid balance sheet, strong ROE, and a very capable management team. Despite those attractive features, the industry's rather low-growth character, along with Medibank's valuation, meant we stayed on the sidelines. Once the October 2022 cybercrime incident became public — it's plainly visible on the chart to the left — we noticed that the count of policyholders stayed fairly stable even with all the bad press and downbeat feeling around that cybercrime. That gave us a good opening to establish a stake in Medibank at a price below what we consider its intrinsic worth. Turning to NAB, mood during that stretch was poor, chiefly for two reasons. Sharply climbing rates made some in the market uneasy about whether borrowers could keep up with their loan payments. On top of that, there was pessimistic feeling stemming from the collapse of regional banks in the U.S. I think the idea is to tune out some of that clamor. Having looked at the industry and the contrasts — I guess — between the Australian sector and the one in the U.S., and having gone over the bank's capital position, we concluded this was a good chance to take advantage of the weakness and add to our holding in NAB. NAB is well capitalized and well provisioned. We like the management team and consider them backable. Their return on equity is solid. And at the time we were purchasing shares, the 9% gross dividend yield was very attractive. One thing we'd point out: after Mark's earlier remarks about preferring businesses that compound earnings over the long run, AMCIL is still underweight the Big 4 banks versus the ASX 200 index. And finally, ALS is a top global lab-testing company that serves the life sciences and commodity sectors. Its Life Sciences division is well placed to take share in an expanding market as testing demand rises. The exit of highly regarded CEO Raj Naran, together with market worries about where the commodity testing cycle is headed, opened up a number of chances to build AMCIL's position — and those should be visible in the green-dot chart Mark pointed to. Evaluating the teams running the companies we back matters a great deal to how we invest. And clearly, whenever a fresh chief executive takes over, we examine that situation with particular care. Malcolm Deane, who now leads the company as CEO, previously held several leadership posts at ALS, including one focused on strategy, and following two meetings with him to date, our early impressions have been rather positive, and with that I'll return the floor to Mark.
Robert Freeman
executiveThanks, Jaye. Turning to Slide 13, we've highlighted three more stocks in which we put money to work during that six-month window. WiseTech is genuinely an impressive company. It met every one of our requirements for an owner-driver business — a solid balance sheet and a high return on capital. As a software provider, it has established a leading position within logistics; some of the biggest logistics firms worldwide are committing to adopt that product. This is an annuities-style operation with a long growth runway. So even though the share price is up, this fits the pattern of a trend continuing. We wanted it represented in the portfolio. Biggest mistake, or perhaps that one is simply not buying enough, but we hold a position and we're glad we have some, though it would have been wonderful to have secured more. Next, turning to Zero and IDP, these were sold in the bucket of price dislocations. So Zero performed very strongly after it first listed on the Australian market, and it became perhaps overpriced, reaching levels near $150; but with some uncertainty regarding the profitability of the business and the capacity to expand overseas, the stock was sold off. There was a CEO change, which introduced a lot of uncertainty. However, the company began to discuss what they are doing to reestablish growth within the company. Also, a few points: they’re reducing the cost base, and a sizable workforce cut and cost-out program were announced; that definitely pushed the market to rethink profitability. Another element they cited was pricing power amid inflation. And with a software offering, you can get considerable leverage flowing through to the bottom line. So during this stretch when the market was somewhat down on it, we took a position, and again, buying more would have been nice, but it shares similar traits—a strong balance sheet, annuity-style revenue streams, sticky customers—and there’s still ample growth to come out of the U.K. Should they manage to make the U.S. function even partially, that would likely deliver additional gains. In any case, we picked up a few shares during that window; and IDP was the final one. IDP—actually, that stands for IDP Education. The company runs two business segments. The first is English language testing, a worldwide operation, while the second is student placement, which is likewise global. Competition exists within the English language testing side of the market. In the majority of markets where they do business, rivals are present. There is a single large market where they basically held a monopoly, and that is Canada. Canada said it would open things up to competition, and that sent the share price down sharply, and in our view that was an overreaction; this company sits on our watch list because if you look at the student placement side of its business, it leads the market, yet it still has a substantial chance to grow share. And I believe market share is roughly 10%; they are putting money into technology, aiming to set themselves apart from rivals. Universities depend on them to bring students into their institutions. So it is a vital business; it carries an exceptionally strong balance sheet; we believe management has a long runway of growth, especially in student placement. That decline let us establish a stake, so we now hold a meaningful position in the business. Ideally that shows you something of a trend, connecting my description of how we invest and the frameworks we apply with how those are now turning into deals inside AMCIL. Turning to the following slide about how the portfolio is set up for what lies ahead — I won't walk through all of these names, but it likely opens things up for questions. Here you're seeing what we term our growth companies. We're looking for the traits of a market leader plus recurring annuity-style revenue that our team can back, along with a solid balance sheet. Those patents are what we look for in the businesses we put money into. Moving on to the next slide. Next we talk about our store companies; we're glad to — it isn't solely about earnings-growth stocks. We're perfectly happy holding store-type businesses like Wesfarmers and Computershare, BHP. Each of them has the characteristics we want in companies: excellent return on capital and good management. And whenever we see price opportunities in them, we're pleased to add. They also give the portfolio stability. We also have businesses that we see as leaning more toward income generation, and NAB is one we recently added as an illustration. Woodside Energy is in there as well, and on certain of these holdings we write call options. With Woodside Energy, our call option coverage is actually fairly substantial. That gives us attractive franked dividends along with additional income from the options. We've written some options on Medibank following a pretty sharp rebound after our purchase. A handful of options on Commonwealth Bank are in place too. On names like these, our options trading expertise lets us generate two income streams at once. After that, we could turn to the outlook and then take questions. Clearly, the global picture for inflation and interest rates is still unclear. Clearly, we recently saw the U.S. raise rates again, this time by 0.25%. But in Australia today, there was no increase. Because of this tightening, both the U.S. and Australian economies are displaying areas of slowdown. In my view, the market had expected a bigger deceleration. What the market had expected was a fairly significant sell-off. The phrase you would use is that investors are maybe getting caught short. And you have seen plenty of buying come back into the market, and markets have held up remarkably well. That simply demonstrates how extremely difficult it is to forecast short-term share market moves, and we are near fully invested. Energy prices, obviously, have remained elevated. There is some declining consumer demand. Certainly, in more recent times, what we are hearing back is that the consumer is slowing. Yet, as I said, I think people expect it to slow really fast, but what we have had from the economy is a gradual slowdown. Some slung in China; so putting these things together, we believe there may perhaps be added pressure on economies ahead and then ultimately on earnings. And I noted that markets have stayed rather buoyant; but on account of that, we are now fairly cautious. Over the past six months, we came across some strong opportunities. In our view, we capitalized on them well, even if there was always room for more. Still, we plan to stay cautious at this point; reporting season is approaching, and companies will be releasing their results. Volatility is usually something we see during that period. And in the names we track closely, we are definitely ready if any chances arise. Should a downturn arrive, no market is ever fully protected. Quality companies also remain a priority for us. As a result, resources are running hot. Take a case in point: there can be periods where our results lag. Still, as we review what we own, our conviction is that these are truly strong enterprises held with a long horizon in mind, and we see them as solid operations capable of producing earnings and dividend growth over time. With that said, let's begin taking your questions.
Geoffrey Driver
executiveThanks, Mark. Just as a reminder, questions can come through the operator or via the website. I have a few questions here regarding stocks. Through the recent weakness, have we added to Macquarie or CSL?
Robert Freeman
executiveWe should clarify one thing. With CSL, we actually already hold a fairly solid position. Looking back, it might have been wise to trim a little. I think it’s beginning to appear as interesting value here. But since our holding is already sizable, we’ll probably just remain a holder, though it’s definitely looking more interesting. As for Macquarie, we have consistently added in DIPs in Macquarie; so again, we probably feel like we’ve got a good position there. That’s Macquarie Group, formerly Macquarie Bank. I should note, we do have another Macquarie, which is Macquarie Technology. They actually did a capital raising during the period. So that was one of those events, again, that gives us an opportunity to buy at fair value. We actually participated in a capital raising they did. So for those who don’t know, Macquarie Technology changed their name slightly; that key business is they actually operate a very strategic data center up in Sydney, and they’re also doing some work around cybersecurity as well but the strategic asset is the data center. And it’s a very interesting company because it’s an owner driver, 2 brothers started the company. They’re still running it. They’ve been very conservative around how it’s financed. They’ve got a great long-term track record. So again, backing the people. But effectively, they’ve got a planning permit at the moment to actually convert their car park. So it’s land they already own. And actually build on that another level — another data center to complement what they’ve already got. And we think that would be a great development if that finally gets ahead. So they wanted to make sure they kept a conservative balance sheet, which is the right thing to do. So we supported that capital raising.
Geoffrey Driver
executiveThat brings us, I suppose, to the question of how concentrated the portfolio is. Does the portfolio have limits on concentration when it comes to individual stocks?
Robert Freeman
executiveOkay, so we trim it in various ways when looking at income, store work, and growth stocks. A few cyclical names sit in there, like ALS and BHP. When we examine our portfolio — the structure that comes to the investment committee — we consider our positions against the index, plus the absolute portfolio. There isn't a hard cap as such, though no single stock, say, carries a position roughly 5% above its index weight. Still, we aren't truly — we keep an eye on the index, yet it doesn't drive us, since we hold fewer than 40 stocks. Concentration is inevitable; so for most of the positions you own, most will be sizable ones once measured against the index.
Geoffrey Driver
executiveThere's one more question regarding returns over 10 years. How would those compare with the ASX Accumulation Index if options trading had not been undertaken; I suppose this returns to the earlier point about how options actually affected the...
Robert Freeman
executiveRight. No, since we really don’t do much of that. I mentioned that tax has been something of a drag. Still, I just think having clarity around the process and staying consistent with it is the key going forward — that’s the key going forward.
Geoffrey Driver
executiveAMCIL puts money right across the market, so the split between large caps and smaller companies has shifted a lot over the last 12 months, with small companies doing worse. What's your view on how the portfolio is positioned?
Robert Freeman
executiveYeah. That's a fair question, since the stocks we hold have in fact shifted in character as time has passed, especially those we've owned for a long while. Take Reece — we first bought in quite a while back — and ResMed has been with us for many years too. A number of these were once what we'd call small caps, then they became mid caps, and now they're turning into large caps. So there have been stretches when we carried more small stocks. More lately we've probably carried fewer, though we suspect opportunities exist there; that's why we added a new position in Gentrack, a newer and rather smaller business. It's another software firm, selling product to the utilities sector, with annuity-style revenue streams. Very conservative accounting, a strong balance sheet — so the same process as always. It really comes down to where opportunity shows up. And as I said, we don't feel any obligation to sit in a particular segment of the market. What we do want is for the universe we screen to span the store-type stocks, large caps, mid caps and some emerging small names; we don't want to avoid those; a couple over the last couple of years didn't work out for us, but we believe we've really zeroed in on the characteristics we seek. After that, it's simply a matter of when value appears. So we genuinely want to go wherever value is. And again, we've shown you a good number of transactions during this period; and should more opportunities emerge in small caps, we'd gladly commit more there.
Geoffrey Driver
executiveThere are a few questions regarding the dividend. I believe this particular one comes from the angle of paying that special dividend. And there is also a fairly long question about dividends, and also about how uneven the size of the dividend we distribute is. And has that kind of put us in a position where investors really don't see the shares as a reliable dividend player, and so that has contributed to the discount on the share price relative to the NTA? And it goes on to ask, given the healthy level of retained profits, reserves and frank credits, and the consistency of earnings, which ranged between $0.022 and $0.027 per share across the past few years, will the Board commit to paying a more consistent dividend over the years ahead?
Robert Freeman
executiveYeah, I’ll hand things over to Andrew shortly. Let me first provide a bit of context. We used to have a policy of distributing all franking, and we moved away from it since, whenever we realized a capital gain, paying the entire amount out made managing the portfolio hard. The difficulty for us now, though, is that by saying we won’t distribute the full amount, franking credits end up sitting in the company. With this dividend, then, what we’re aiming for is a balance: an operating amount paid from operating income, and then deciding how far we want to supplement that with a special dividend from some capital gains, without feeling compelled to pay everything out, which would limit our ability to invest; but...
Andrew J. Porter
executiveYes, that summary is fairly close to the mark. Let me clarify: the final dividend comes to $0.025, which is the same figure we've distributed for the last couple of years. An interim dividend of $0.01 has been paid, and that's also been the case for the past couple of years, and in addition to that we've included a special dividend of $0.015. The reason is that, as Mark noted, franking credits are not reflected on our balance sheet at the point they are generated. So the tax has been paid out, yet they don't form part of your NTA. Consequently, if those franking credits are not distributed, then your portfolio performance and the returns to the shareholder can be impacted. Those franking credits are worth nothing unless they get distributed to shareholders. That's why the Board weighs keeping dividends steady against letting shareholders actually use the franking credits that have built up. Whether that moves the share price, I can't say—but we have another company, Mirrabooka, part of the LIC stable. Its dividend could fairly be called very inconsistent: it pays just $0.10 every year, plus specials that vary annually with performance; at the end of June it was trading at a discount. Every LIC in the state where the majority of LICs on the index were, that was due to rising interest rates, which meant equity investments had somewhat fallen out of paper. But historically, Mirrabooka has traded at quite decent premiums; and the lumpiness of the dividend, including special dividends, has not Mirrabooka. So I don't have a crystal ball. I can't see what drives all shareholders, but generally, we think it's the LIC's performance and the shares' liquidity that have the major impacts on the share price.
Robert Freeman
executiveAnd the reason behind my wanting that dividend: we clearly rolled out a $0.01 interim dividend as an attempt, and we recognize it comes across as rather uneven across the 2 periods. Still, I believe this is likely something the Board will take up as we move forward, maybe at the point when we review the next interim dividend, since we get that a steadier dividend split across the 2 halves matters to investors, though it remains something we're examining going forward.
Geoffrey Driver
executiveRight, and as Andrew mentioned, the discount issue stems from several different things — fund size, how liquid the shares are, and performance too. And obviously, some of those elements may currently be working against us. Then there's the other question: the MER looks elevated next to somewhat larger LICs. As Andrew noted, it has moved quite a bit across the past couple of years. I mean, it's returned to where it has historically sat. In 2020 it was 0.66%, and in 2019 it was 0.72%. So we still believe that — and we do run a comparison against other investment vehicles — even at 0.66%, it remains a relatively low-cost vehicle. It would probably come down as the portfolio improves, it would be.
Robert Freeman
executiveAnd obviously, there's no performance fees on that.
Geoffrey Driver
executiveYeah, back to the stocks question. Could you lay out your investment thesis on Braintree, and also say whether you took part in the capital raising in May? Specifically, can you speak to when you expect that business to become free cash flow positive, and how confident we are in the company clear?
Robert Freeman
executiveYes, thanks. So, this is a business that joined the portfolio a few years back. Looking back, we probably moved too soon—perhaps we shouldn't have invested at that point—but since it's in the portfolio, we've put more effort into it as we go forward. The company provides software to the health care sector. It isn't profitable yet, though it's getting close. We carried out a capital raise in May, and yes, we took part in it. We're meeting with management once more. It has many of the traits we look for, particularly the business model with recurring annuity revenue. Those in charge of the company hold substantial equity stakes. Their projection — and our hope — is that this marks the final capital raise through '25, and that they turn cash flow positive in '24, cash flow positive in '24. They're also landing some notable customers. That's exactly the outcome we want to see. Should they continue bringing in strong customers, we'll gladly remain invested. The management team is doing a solid job running things, and we appreciate the meaningful equity stake they hold along with the sizable market opportunity. So our current leaning is that exiting right now would probably be premature, since several of the traits we want to see are beginning to fall into place. It remains somewhat higher on the risk spectrum. That said, as I mentioned, the specific criteria we've set for this company—and over the last six or seven months particularly—it has been meeting those benchmarks, and we'll watch how things develop going forward.
Geoffrey Driver
executiveThanks, Mark. Just a quick reminder that you can submit a question via the website or by phone. We have a question here regarding the outlook for iron ore in China. What are your views on that, especially when it comes to dividends for our holdings?
Robert Freeman
executiveRight, so the iron ore price has actually held up remarkably well. It’s still sitting at about $117 a tonne, which remains comfortably above where the market’s longer-term expectations sit, even if those longer-term expectations have been gradually rising over time. That said, probably — we do like BHP. I think we like Rio as well, though we don’t own Rio right now. We like the mix and how BHP has steadily built its copper exposure. Over the very long run, potash could deliver something for them. So overall we like that business, but we’re somewhat more cautious on the iron ore price, because increasingly China has to source more of its growth from the consumer instead of continuing these big asset builds; and I think that point is widely understood. I think it has been difficult for China to make that shift. The economy’s growth rates have slowed, but we remain probably a bit cautious that over the longer term the iron ore price will come off. In the very long run, we expect to see at some stage iron ore coming out of Africa, and that is very high quality iron ore. And as we know, with commodities, modest increases in volume can move prices quite a lot. So that probably leaves us with a more conservative exposure. In the meantime, though, the company is well set up, and that’s why we hold some of it — to pass their profits into shareholders through frank dividends.
Geoffrey Driver
executiveIs there value to be found in other consumer discretionary names that aren't in your portfolio right now? And if yes, which ones?
Robert Freeman
executiveThere are a few of them, and a few that we like. As we said, we purchased the DIPs in those stocks; we brought up ARBs and Reece; and our position in Temple & Webster has been kept; we trimmed a small amount from it just to reduce risk somewhat. Still, those stocks did extremely well. It's noteworthy, some of the updates coming from Temple & Webster. In case you aren't familiar, they operate as an online retailer. A lot of household furniture and goods get sold by them. However, they function purely as a marketplace, meaning they don't actually carry inventory themselves. That makes it a capital light model. And even through this weak period, their sales figures have held up far, far better in the market. So it shows that people shopping for furniture recognize the value Temple & Webster provides. And so that business has held up really nicely. Net cash sits on their balance sheet. It's an owner-driver business. So a position in that one has been maintained by us. And we hold a small stake in Revel. But again, thus far, the business there has held up very well. Likely that's because it's a global business. They're expanding into new markets, which perhaps gives that company a buffer, since there are plenty of regions, especially in Europe and still in the U.S., where growth continues for them. So look, a few other stocks get looked at by us. I mean Wesfarmers is also a consumer discretionary; JB Hi-Fi strikes us as a good company. That's potentially on our watch list because we still regard it as a very good business. We consider it great quality, with high return on capital and good frank dividends. So those are probably the main ones, though we're wary of more cyclical type stocks.
Geoffrey Driver
executiveThanks, Mark. I’ll finish up here for about another question. Has there been any thought given to establishing a presence in Washington? So that’s.
Robert Freeman
executiveNo. That group of companies is definitely on our radar. Still, our aim is to remain true to putting money into a real operating business that we can genuinely wrap our minds around. That’s where our attention lies.
Geoffrey Driver
executiveOkay, thank you, Mark. Well, we don't have any further questions coming in either online or over the phone, so I'll give it back to you to close things out.
Robert Freeman
executiveAll right, and thanks to all of you for joining. Clearly, there are now, I suppose, 4 main moments across the year when you can get updates on AMCIL, beginning in January. From here on, one webinar like this will be held for the half year results. In March, we'll be running investor road shows across the country, so you can come along, meet us, put questions to us, and hold us accountable. And of course, there's this presentation for the full year result in July. Then in October, the AGM will be webcast. So there are plenty of chances to hear from AMCIL and find out how things are going. And I hope we've managed to give you a bit more clarity today on the process we're undertaking, the frameworks we use, and some examples of how we put that into action. So thank you all for attending, and I hope we can meet in person at some point. Thank you.
Operator
operatorThat brings us to the end of today's conference call. We appreciate everyone taking part. You can go ahead and disconnect your lines now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete AMCIL Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to AMCIL Limited earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in AMCIL Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.